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Outline 
Overview of regulatory science activities in FDA 
  1. Current activities 
  2. Key challenges 
  3. Future directions 
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FDA Nanotechnology  
Regulatory Science Activities 
I. Agency and  
Center-level 
 
III. International  
Interactions 
II. Interactions with  
domestic  
stakeholders 
 
IV. Regulatory  
Science Initiative 
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FDA Activities 
I. Agency and Center-level 
 
1.  Nanotechnology Task Force  
2.  Intramural research programs 
3.  Nanotechnology Regulatory Science Plan  
4.  Agency- and Center-level policy documents 
5.  Ongoing review of products 
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FDA Activities (cont’d) 
II. Interactions with domestic stakeholders 
1. USG partnerships 
 - National Nanotechnology Initiative  
 - WH Emerging Technologies- Inter-Agency Policy Coordination 
2. Ongoing interactions with US regulatory agencies 
 - EPA 
 - CPSC 
 - NIEHS  
3. Collaboration 
  - Universities 
  - NIH, NCI-NCL 
  - NIST 
4. Public meetings 
 - 2006 with industry, consumers, other stakeholders  
 - 2008 Public Meeting  
 - CDRH public workshop in 2010 
6 
FDA Activities (cont.) 
III. International Interactions  
 
1. Ongoing communication with international 
regulatory agencies (EU, UK, Japan, Australia, 
Canada) 
2. Participation in standards-setting bodies  
 - ISO TC 229 
 - ASTM 
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FDA Activities (cont.)  
IV. Regulatory Science Initiative 
 
  1- Initiate CORES (Collaborative Opportunities for  
 Research Excellence) Program 
 
2- Enhance Laboratory capacity to assess  
nanotechnology products and their safety 
 
3- Promote staff development and training 
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Key challenges for development and 
deployment of nano-based products  
• Evolving state of science - - Mechanistic 
understanding and test methods 
• Risk management challenges in case-by-case 
evaluation 
• Current regulations are flexible so as to 
incorporate new emerging fields such as 
nanotechnology  
• Guidance documents are continuing to evolve 
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Guidance Documents 
• FDA 
 - Draft guidance published for comments  
 http://www.fda.gov/ScienceResearch/SpecialTopics/Nanotechnology/ucm257926.htm 
• CDER 
 - Drugs containing nanomaterials are like any new drug. 
 - Many published Guidance documents,  
  -- are applicable and  
  -- may be used by sponsors. 
• CDRH 
 - In preparation 
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Gaps remain in developing test methods 
and standards 
 
 - Identification and assessment of nanoscale 
materials in products 
 - characterization methods 
 - biocompatibility and toxicity assessment 
 
 
    Future directions 
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Implementation of 2011 FDA 
Nanotechnology 
Regulatory Science Program 
 
  1- Initiate CORES (Collaborative Opportunities for  
 Research Excellence) Program 
 
2- Enhance Laboratory capacity to assess  
nanotechnology products and their safety 
 
3- Promote staff development and training 
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Collaborative Opportunities 
for Research Excellence in Science (CORES) 
Objectives 
• Support for research projects in nanotechnology regulatory science 
priority areas 
• Emphasis on inter-agency projects 
– Enhanced coordination through NNI 
– CPSC, EPA, NIH, NIST, NSF, DARPA 
• Support for joint FDA-Academia projects 
– Enhanced safety, toxicity programs 
– Development of internal FDA research priorities 
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FDA 2011Nanotechnology Initiative- 
Examples of Current  Regulatory Research Areas  
  
1. Physico-Chemical Characterization in FDA-Regulated Products 
      - Improved methods and tools to detect and measure the physical structure, chemical 
properties, and safety of nanomaterials in FDA-regulated products:  
2. Nonclinical Modeling of Nanomaterials in FDA-Regulated Products 
      - Develop and evaluate in vitro and in vivo assays and models to assess safety and/or 
efficacy of nanomaterials in FDA-regulated products, in order to:  
3. Risk Characterization Information 
     - Enhance the understanding of hazard identification, exposure science, and risk 
modeling  
4. Risk Assessment 
     - Enhance state of knowledge and scientific evidence to support potential development 
of generalized class-based approaches to risk assessment 
(http://www.fda.gov/ScienceResearch/SpecialTopics/Nanotechnology/ucm196697.htm)  
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Summary 
• FDA mission 
 - Protecting public health and fostering innovation 
• Evolving science continues to address gaps:  
 - Identification and assessment of nanoscale materials in 
products 
 - characterization methods 
 - biocompatibility and toxicity assessment 
15 
More information available at 
FDA Websites 
 
http://www.fda.gov/ScienceResearch/SpecialTopics/Nanotechnology/default.htm 
http://www.fda.gov/Training/CDRHLearn/default.htm 
Overview of Regulatory Requirements: Medical Devices  
     Quality System Regulation 21 CFR Part 820 Basic Introduction  
      Device Establishment Registration and Listing 
      Overview of the Premarket Notification Process – 510(k) 
      Bioresearch Monitoring (BIMO)  
http://www.fda.gov/cdrh/devadvice/ 
http://www.fda.gov/cder/drug/default.htm 
Investigational New Drug Application (21 CFR Part 312)  
Applications for FDA Approval of a Biologic License (21 CFR Part 601 
http://www.fda.gov/ScienceResearchSpecialTopics/Nanotechnology/default.htm 
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Measurements and Standards 
Reference Value Mean Size and Expanded Uncertainty (a) 
Average Particle Size (Diameter), in nm 
 
 
Technique Analyte Form Particle Size 
(nm) 
Atomic Force Microscopy dry, deposited on substrate 8.5 ± 0.3 
 
Scanning Electron Microscopy dry, deposited on substrate 9.9 ± 0.1 
 
Transmission Electron 
Microscopy 
dry, deposited on substrate 8.9 ± 0.1 
 
Differential Mobility Analysis dry, aerosol 11.3 ± 0.1 
 
Dynamic Light Scattering liquid suspension 13.5 ± 0.1 
 
Small-Angle X-ray Scattering liquid suspension 9.1 ± 1.8 
NIST Report of Investigation, Reference Material 8011, Gold Nanoparticles, Nominal 10 nm Diameter 
